Kiniksa Pharmaceuticals International, plc Insider Trading

KNSA

Last 12 months

Insiders sold $108M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. Director G Bradley Cole sold 299K on Jul 29, 34% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$108M

0 buys · 28 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

None

in the last two years

Get an email when KNSA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 30 – Nov 3	Sanj K Patel Chairman & CEO	Sold10b5-1 plan 15 parts	402,494	$92.92 average	$37.4M	29%	Form 4
Nov 2	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan 4 parts	36,783	$92.16 average	$3.39M	64%	Form 4
Oct 30 – Nov 2	John F. Paolini Chief Medical Officer	Sold10b5-1 plan 10 parts	96,000	$93.09 average	$8.94M	58%	Form 4
Oct 30 – Nov 2	Ross Moat Chief Operating Officer	Sold10b5-1 plan 11 parts	103,585	$92.93 average	$9.63M	91%	Form 4
Oct 30	Michael R Megna Chief Accounting Officer	Sold10b5-1 plan 7 parts	36,260	$94.43 average	$3.42M	74%	Form 4
Sep 3	Michael R Megna Chief Accounting Officer	Sold10b5-1 plan	4,600	$80.30	369K	14%	Form 4
Jul 29	G Bradley Cole Director	SoldNo plan	3,673	$81.43	299K	34%	Form 4
May 1	John F. Paolini Chief Medical Officer	Sold10b5-1 plan 2 parts	58,424	$53.71 average	$3.14M	47%	Form 4
May 1	Sanj K Patel Chairman & CEO	Sold10b5-1 plan	48,565	$54.02	$2.62M	17%	Form 4
Apr 28 – 30	Sanj K Patel Chairman & CEO	Sold10b5-1 plan 6 parts	508,339	$51.96 average	$26.4M	68%	Form 4
Apr 28	Barry D Quart Director	Sold10b5-1 plan	13,099	$50.10	656K	51%	Form 4
Apr 9	Ross Moat Chief Operating Officer	Sold10b5-1 plan	1,703	$46.69	80K	12%	Form 4
Apr 9	Michael R Megna Chief Accounting Officer	Sold10b5-1 plan	6,625	$46.69	309K	19%	Form 4
Apr 6	Ross Moat Chief Operating Officer	Sold10b5-1 plan	2,367	$48.58	115K	15%	Form 4
Apr 6	Sanj K Patel Chairman & CEO	Sold10b5-1 plan	7,278	$50.01	364K	3.0%	Form 4
Apr 6	Barry D Quart Director	Sold10b5-1 plan	6,901	$50.00	345K	35%	Form 4
Mar 9	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan 2 parts	36,722	$45.92 average	$1.69M	75%	Form 4
Mar 2	John F. Paolini Chief Medical Officer	Sold10b5-1 plan 3 parts	40,000	$44.82 average	$1.79M	39%	Form 4
Feb 10 – 12	Barry D Quart Director	Sold10b5-1 plan 2 parts	2,800	$45.00 average	126K	18%	Form 4
Feb 9	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan 2 parts	17,845	$43.28 average	772K	60%	Form 4
Feb 2 – 4	Barry D Quart Director	Sold10b5-1 plan 3 parts	15,960	$45.22 average	722K	56%	Form 4
Jan 8	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan	12,000	$41.89	503K	39%	Form 4
Dec 15, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan	12,048	$41.56	501K	42%	Form 4
Dec 15, 2025	Barry D Quart Director	Sold10b5-1 plan	20,129	$41.51	836K	62%	Form 4
Dec 8, 2025	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan	42,841	$41.49	$1.78M	58%	Form 4
Nov 26, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan	200	$42.89	9K	0.9%	Form 4
Nov 17, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan 2 parts	12,470	$41.24 average	514K	35%	Form 4
Nov 12, 2025	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan	19,900	$40.94	815K	39%	Form 4
Oct 31, 2025	John F. Paolini Chief Medical Officer	Sold10b5-1 plan	82,542	$37.14	$3.07M	57%	Form 4
Oct 28, 2025	Mark Ragosa Chief Financial Officer	Sold10b5-1 plan	100	$41.00	4K	0.3%	Form 4
Oct 20, 2025 – Oct 22, 2025	Sanj K Patel Chairman & CEO	Sold10b5-1 plan 4 parts	257,969	$38.86 average	$10M	54%	Form 4
Oct 20, 2025	Michael R Megna Chief Accounting Officer	Sold10b5-1 plan 2 parts	50,490	$38.87 average	$1.96M	65%	Form 4
Oct 14, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan 2 parts	12,368	$37.67 average	466K	30%	Form 4
Sep 29, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan	42,000	$38.33	$1.61M	55%	Form 4
Sep 15, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan 2 parts	16,400	$36.46 average	598K	32%	Form 4
Sep 4, 2025 – Sep 5, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan 2 parts	98,660	$35.54 average	$3.51M	69%	Form 4
Sep 4, 2025	Ross Moat Chief Corp. & Comm. Officer	Sold10b5-1 plan	3,523	$35.31	124K	27%	Form 4
Sep 3, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan	15,091	$35.50	536K	25%	Form 4
Sep 3, 2025	Michael R Megna Chief Accounting Officer	Sold10b5-1 plan	11,000	$34.84	383K	22%	Form 4
Aug 18, 2025	Eben Tessari Chief Operating Officer	Sold10b5-1 plan 2 parts	16,200	$33.77 average	547K	29%	Form 4

Oct 30 – Nov 310b5-1 plan
Sanj K Patel
Chairman & CEO · sold 402,494 at avg $92.92
$37.4M
29% of stake
Nov 210b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 36,783 at avg $92.16
$3.39M
64% of stake
Oct 30 – Nov 210b5-1 plan
John F. Paolini
Chief Medical Officer · sold 96,000 at avg $93.09
$8.94M
58% of stake
Oct 30 – Nov 210b5-1 plan
Ross Moat
Chief Operating Officer · sold 103,585 at avg $92.93
$9.63M
91% of stake
Oct 3010b5-1 plan
Michael R Megna
Chief Accounting Officer · sold 36,260 at avg $94.43
$3.42M
74% of stake
Sep 310b5-1 plan
Michael R Megna
Chief Accounting Officer · sold 4,600 at $80.30
369K
14% of stake
Jul 29No plan
G Bradley Cole
Director · sold 3,673 at $81.43
299K
34% of stake
May 110b5-1 plan
John F. Paolini
Chief Medical Officer · sold 58,424 at avg $53.71
$3.14M
47% of stake
May 110b5-1 plan
Sanj K Patel
Chairman & CEO · sold 48,565 at $54.02
$2.62M
17% of stake
Apr 28 – 3010b5-1 plan
Sanj K Patel
Chairman & CEO · sold 508,339 at avg $51.96
$26.4M
68% of stake
Apr 2810b5-1 plan
Barry D Quart
Director · sold 13,099 at $50.10
656K
51% of stake
Apr 910b5-1 plan
Ross Moat
Chief Operating Officer · sold 1,703 at $46.69
80K
12% of stake
Apr 910b5-1 plan
Michael R Megna
Chief Accounting Officer · sold 6,625 at $46.69
309K
19% of stake
Apr 610b5-1 plan
Ross Moat
Chief Operating Officer · sold 2,367 at $48.58
115K
15% of stake
Apr 610b5-1 plan
Sanj K Patel
Chairman & CEO · sold 7,278 at $50.01
364K
3.0% of stake
Apr 610b5-1 plan
Barry D Quart
Director · sold 6,901 at $50.00
345K
35% of stake
Mar 910b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 36,722 at avg $45.92
$1.69M
75% of stake
Mar 210b5-1 plan
John F. Paolini
Chief Medical Officer · sold 40,000 at avg $44.82
$1.79M
39% of stake
Feb 10 – 1210b5-1 plan
Barry D Quart
Director · sold 2,800 at avg $45.00
126K
18% of stake
Feb 910b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 17,845 at avg $43.28
772K
60% of stake
Feb 2 – 410b5-1 plan
Barry D Quart
Director · sold 15,960 at avg $45.22
722K
56% of stake
Jan 810b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 12,000 at $41.89
503K
39% of stake
Dec 15, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 12,048 at $41.56
501K
42% of stake
Dec 15, 202510b5-1 plan
Barry D Quart
Director · sold 20,129 at $41.51
836K
62% of stake
Dec 8, 202510b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 42,841 at $41.49
$1.78M
58% of stake
Nov 26, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 200 at $42.89
9K
0.9% of stake
Nov 17, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 12,470 at avg $41.24
514K
35% of stake
Nov 12, 202510b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 19,900 at $40.94
815K
39% of stake
Oct 31, 202510b5-1 plan
John F. Paolini
Chief Medical Officer · sold 82,542 at $37.14
$3.07M
57% of stake
Oct 28, 202510b5-1 plan
Mark Ragosa
Chief Financial Officer · sold 100 at $41.00
4K
0.3% of stake
Oct 20, 2025 – Oct 22, 202510b5-1 plan
Sanj K Patel
Chairman & CEO · sold 257,969 at avg $38.86
$10M
54% of stake
Oct 20, 202510b5-1 plan
Michael R Megna
Chief Accounting Officer · sold 50,490 at avg $38.87
$1.96M
65% of stake
Oct 14, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 12,368 at avg $37.67
466K
30% of stake
Sep 29, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 42,000 at $38.33
$1.61M
55% of stake
Sep 15, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 16,400 at avg $36.46
598K
32% of stake
Sep 4, 2025 – Sep 5, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 98,660 at avg $35.54
$3.51M
69% of stake
Sep 4, 202510b5-1 plan
Ross Moat
Chief Corp. & Comm. Officer · sold 3,523 at $35.31
124K
27% of stake
Sep 3, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 15,091 at $35.50
536K
25% of stake
Sep 3, 202510b5-1 plan
Michael R Megna
Chief Accounting Officer · sold 11,000 at $34.84
383K
22% of stake
Aug 18, 202510b5-1 plan
Eben Tessari
Chief Operating Officer · sold 16,200 at avg $33.77
547K
29% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KNSA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KNSA

CompareIntrinsic value

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

COLLCollegium Pharmaceutical Inc.

$23.56-0.72%98

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

Held by ETFs

KNSA is in 54 US ETFs. The largest of them, with KNSA's weight in each:

Spot a number that looks wrong? Check it in KNSA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KNSA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.